Placebo | Metformin | Lifestyle | |||||||
Statin use | No statin use | p | Statin use | No statin use | p | Statin use | No statin use | p | |
Fasting glucose (mg/dL) | 3.0 | 1.9 | 0.04 | −0.3 | −1.3 | 0.03 | 0.8 | −0.4 | 0.007 |
Two-hour glucose (mg/dL) | −2.2 | −3.9 | 0.38 | −2.8 | −7.3 | 0.01 | −5.6 | −10.9 | 0.001 |
Glycated hemoglobin (%) | 0.04 | −0.01 | <0.01 | −0.03 | −0.09 | <0.001 | −0.05 | −0.11 | <0.001 |
Insulinogenic Index | −0.21 | 3.83 | 0.42 | −7.45 | −3.85 | 0.44 | −8.54 | 1.66 | 0.01 |
Fasting insulin (µU/mL) | 2.76 | 2.61 | 0.83 | −1.44 | −0.93 | 0.43 | 0.64 | −0.19 | 0.16 |
Body mass index (kg/m2) | 0.14 | 0.12 | 0.84 | −0.29 | −0.53 | 0.04 | −0.76 | −0.92 | 0.06 |
Mean changes from baseline are estimated with adjustment for baseline value from mixed models according to use of statin at time of the assessment with p values to indicate difference by statin therapy within treatment groups. Changes after the development of diabetes were excluded in the analyses.